Literature DB >> 20831496

Cardiac toxicity and radiation dose to the heart in definitive treated non-small cell lung cancer.

Tine Schytte, Olfred Hansen, Thomine Stolberg-Rohr, Carsten Brink.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20831496     DOI: 10.3109/0284186X.2010.504736

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  11 in total

Review 1.  Cardiac toxicity of lung cancer radiotherapy.

Authors:  Radovan Vojtíšek
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-14

2.  Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

Authors:  Kyle Wang; Michael J Eblan; Allison M Deal; Matthew Lipner; Timothy M Zagar; Yue Wang; Panayiotis Mavroidis; Carrie B Lee; Brian C Jensen; Julian G Rosenman; Mark A Socinski; Thomas E Stinchcombe; Lawrence B Marks
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 50.717

Review 3.  Radiation-induced heart disease in lung cancer radiotherapy: A dosimetric update.

Authors:  Xin Ming; Yuanming Feng; Chengwen Yang; Wei Wang; Ping Wang; Jun Deng
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

4.  The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients.

Authors:  Laura K McNew; Stephen R Bowen; Olga Gopan; Matthew J Nyflot; Shilpen A Patel; Jing Zeng; Ramesh Rengan
Journal:  Adv Radiat Oncol       Date:  2017-02-01

5.  Dose surface maps of the heart can identify regions associated with worse survival for lung cancer patients treated with radiotherapy.

Authors:  Alan McWilliam; Chloe Dootson; Lewis Graham; Kathryn Banfill; Azadeh Abravan; Marcel van Herk
Journal:  Phys Imaging Radiat Oncol       Date:  2020-07-30

6.  Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose.

Authors:  Joshua R Niska; Jiuyun Hu; Jing Li; Michael G Herman; Cameron S Thorpe; Steven E Schild; Mirek Fatyga
Journal:  J Cancer Ther       Date:  2021-09-29

7.  Evaluation of the hybrid-dynamic conformal arc therapy technique for radiotherapy of lung cancer.

Authors:  Sung Joon Kim; Jeong Won Lee; Min Kyu Kang; Jae-Chul Kim; Jeong Eun Lee; Shin-Hyung Park; Mi Young Kim; Seoung-Jun Lee; Soo-Ho Moon; Byoung-Soo Ko
Journal:  Radiat Oncol J       Date:  2018-09-30

8.  Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.

Authors:  Xin Sun; Yu Men; Jianyang Wang; Yongxing Bao; Xu Yang; Maoyuan Zhao; Shuang Sun; Meng Yuan; Zeliang Ma; Zhouguang Hui
Journal:  Thorac Cancer       Date:  2021-03-16       Impact factor: 3.500

9.  A Pilot Study of Safer Radiation Dosage to the Heart and Its Subregions.

Authors:  Rita Steponavičienė; Justinas Jonušas; Romualdas Griškevičius; Jonas Venius; Saulius Cicėnas
Journal:  Medicina (Kaunas)       Date:  2021-03-31       Impact factor: 2.430

10.  Cardiac Exposure in the Dynamic Conformal Arc Therapy, Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy of Lung Cancer.

Authors:  Xin Ming; Yuanming Feng; Huan Liu; Ying Zhang; Li Zhou; Jun Deng
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.